Doctors meet in Campinas to discuss Inflammatory Bowel Diseases

Doctors meet in Campinas to discuss Inflammatory Bowel Diseases

Inflammatory Bowel Diseases (IBDs) are increasingly being discussed and studied worldwide. This is because, with the advancement of technology, diagnoses have become clearer and more accurate and its prevalence is already 100 confirmed cases for every 100,000 inhabitants in Brazil. For more than 20 years, the Brazilian Organization for Crohn’s Disease and Colitis (Gediib) has been dedicated to bringing together doctors and health professionals who are specialists in this subject, with the aim of providing more quality of life to affected patients.

Annually, since 2019, the entity promotes the Brazilian Week of Inflammatory Bowel Diseases (Sebradii), an event that brings together professionals worldwide to discuss IBDs. This year, the event resumes the face-to-face format, without leaving the online one, and takes place between August 24th and 28th in Campinas, bringing together doctors from all over the world.

“Sebradii is a very broad event, which aims to bring together renowned professionals from around the world, in order to discuss together Inflammatory Bowel Diseases, patient cases, solutions, new technologies in procedures, treatments and medicines. A moment of great exchange of knowledge and evolution for everyone”, informs the president of Gediib, the coloproctologist and digestive system surgeon, Rogério Saad-Hossne.

Among the highlights worldwide are Marc Ferrante (Belgium), Samir Shah (USA), Joana Torres (Portugal), Jana Al Hashash (USA). Also within the broad program of the event is the 2nd PANCCO Latin American Forum, including a project to certify centers of excellence/reference in IBD at the Latin American level, with Colombia as the first country to go through the quality certification process. .

Inflammatory bowel diseases (IBD) constitute a heterogeneous group of immune-mediated inflammatory diseases of the digestive tract, whose main representatives are Crohn’s disease and ulcerative colitis. Clinical presentations vary depending on the extent, severity and form of presentation, with the main symptoms being abdominal pain, diarrhea and bleeding in the stool.

In the most severe forms, the carrier of the disease may present systemic involvement such as weight loss and fever or serious complications requiring surgery.

Although they are still considered rare diseases, whose prevalence should be less than 65/100,000 inhabitants, more recent data have shown an increase in the number of cases of IBD in Brazil in recent years, from 52 to a rate of 100 patients/100,000 inhabitants. , 56.53% with ulcerative colitis and 22.68% with Crohn’s disease.

The upward trend is already 9.57 new cases for every 100,000 inhabitants per year. The consequence of this growth will directly or indirectly impact the entire public and private health system in the country, which, combined with the current difficulties of access, will impact the quality of life of patients.

The main difference between Crohn’s disease (CD) and ulcerative colitis (UC) is in the location where they are installed and in the depth of inflammation, respectively: from the mouth to the anus, which can generate fistulas (connections) and stenosis (narrowings) by reach all layers of the intestine, in CD; and restricted to the (superficial) mucosa of the rectum and large intestine, in UC.

The diagnosis is established based on symptoms such as diarrhea, bleeding and abdominal pain, and complementary tests such as blood, stool, tomography or magnetic resonance imaging, with colonoscopy with biopsy being the main one to establish the diagnosis.

The disease, which affects more young people between 17-40 years old, can compromise the quality of life of its patients and lead to functional incapacity, with leave of up to 314 days from work by the INSS, in a national study that evaluated a period of 5 years.

More information about the 3rd Sebradii on the website .

#Doctors #meet #Campinas #discuss #Inflammatory #Bowel #Diseases

Leave a Comment

Your email address will not be published.